PDC*line Pharma

About PDC*line Pharma

PDC*line Pharma develops off‑the‑shelf therapeutic cancer vaccines using a proprietary allogeneic plasmacytoid dendritic cell line (PDC*line). The platform enables rapid loading of tumor‑associated peptide antigens to generate potent CD8⁺ T‑cell responses, offering scalable, consistent manufacturing and flexibility to target multiple cancer types, with clinical programs in melanoma, lung and colorectal cancers.

<problem>Current cancer immunotherapies that use dendritic cells are limited by complex manufacturing, high variability, and the need for patient-specific cell preparation, which restricts scalability and rapid deployment across multiple tumor types.</problem> <solution>PDC*line Pharma develops off‑the‑shelf therapeutic cancer vaccines using a proprietary allogeneic plasmacytoid dendritic cell line (PDC*line). The platform enables rapid loading of tumor‑associated peptide antigens to generate potent cytotoxic CD8⁺ T‑cell responses. Because the cell line is manufactured at scale, vaccines can be produced in large, consistent batches and administered without individualized cell processing. Clinical programs currently evaluate PDC*lung01 in lung cancer (combined with pembrolizumab) and PDC*neo in colorectal cancer, with earlier phase data showing promising efficacy in melanoma and lung cancer. The approach aims to provide a versatile, scalable immunotherapy that can be quickly adapted to new antigens and cancer indications.</solution> <features> - Proprietary allogeneic plasmacytoid dendritic cell line offering higher potency than conventional dendritic cells for CD8⁺ T‑cell activation - Off‑the‑shelf manufacturing enables large‑scale, consistent production and reduces logistical complexity - Flexible antigen loading allows rapid generation of vaccines targeting diverse tumor antigens, including neoantigens - Clinical-stage programs in melanoma, lung, and colorectal cancers with combination strategies (e.g., pembrolizumab) - Robust preclinical and early clinical data demonstrating strong cytotoxic immune responses and favorable safety profile </features> <target_audience>Primary customers are oncology pharmaceutical companies and clinical researchers seeking scalable, antigen‑specific cancer vaccine platforms for combination immunotherapy trials.</target_audience>

What does PDC*line Pharma do?

PDC*line Pharma develops off‑the‑shelf therapeutic cancer vaccines using a proprietary allogeneic plasmacytoid dendritic cell line (PDC*line). The platform enables rapid loading of tumor‑associated peptide antigens to generate potent CD8⁺ T‑cell responses, offering scalable, consistent manufacturing and flexibility to target multiple cancer types, with clinical programs in melanoma, lung and colorectal cancers.

Where is PDC*line Pharma located?

PDC*line Pharma is based in La Tronche, France.

When was PDC*line Pharma founded?

PDC*line Pharma was founded in 2014.

How much funding has PDC*line Pharma raised?

PDC*line Pharma has raised $13.3M.

Who founded PDC*line Pharma?

PDC*line Pharma was founded by Laurent LEVY.

  • Laurent LEVY - Co-founder, Board member & COO/CFO
Location
La Tronche, France
Founded
2014
Funding
$13.3M
Employees
9 employees
Investors
Korea Investment Partners
PL

PDC*line Pharma

Inactive

PDC*line Pharma develops off‑the‑shelf therapeutic cancer vaccines using a proprietary allogeneic plasmacytoid dendritic cell line (PDC*line). The platform enables rapid loading of tumor‑associated peptide antigens to generate potent CD8⁺ T‑cell responses, offering scalable, consistent manufacturing and flexibility to target multiple cancer types, with clinical programs in melanoma, lung and colorectal cancers.

La Tronche, FranceFounded 201495K+ followers9/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 2 months ago

Funding

$13.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

7O
Funding rounds are not available yet.

Founders

Product

Problem

Current cancer immunotherapies that use dendritic cells are limited by complex manufacturing, high variability, and the need for patient-specific cell preparation, which restricts scalability and rapid deployment across multiple tumor types.

Solution

PDC*line Pharma develops off‑the‑shelf therapeutic cancer vaccines using a proprietary allogeneic plasmacytoid dendritic cell line (PDC*line). The platform enables rapid loading of tumor‑associated peptide antigens to generate potent cytotoxic CD8⁺ T‑cell responses. Because the cell line is manufactured at scale, vaccines can be produced in large, consistent batches and administered without individualized cell processing. Clinical programs currently evaluate PDC*lung01 in lung cancer (combined with pembrolizumab) and PDC*neo in colorectal cancer, with earlier phase data showing promising efficacy in melanoma and lung cancer. The approach aims to provide a versatile, scalable immunotherapy that can be quickly adapted to new antigens and cancer indications.

Target Audience

Primary customers are oncology pharmaceutical companies and clinical researchers seeking scalable, antigen‑specific cancer vaccine platforms for combination immunotherapy trials.

Features

  • Proprietary allogeneic plasmacytoid dendritic cell line offering higher potency than conventional dendritic cells for CD8⁺ T‑cell activation
  • Off‑the‑shelf manufacturing enables large‑scale, consistent production and reduces logistical complexity
  • Flexible antigen loading allows rapid generation of vaccines targeting diverse tumor antigens, including neoantigens
  • Clinical-stage programs in melanoma, lung, and colorectal cancers with combination strategies (e.g., pembrolizumab)
  • Robust preclinical and early clinical data demonstrating strong cytotoxic immune responses and favorable safety profile
1
This profile is AI-generated and may contain inaccuracies.